Table 3.

Summary of ongoing NCT registered clinical trials of Natural Killer cell-based therapies for COVID-19 (updated on January 28, 2024).

NCT number	Title	Study Design	Specification of the biological product	Number of patients	Phase/Status	Location
NCT04634370	Phase I Clinical Trial on NK Cells for COVID-19	Single arm	Natural Killer Cells infusion	24	Unknown	Brazil
NCT04900454	Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19	Single Group Assignment	Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells	18	Unknown	USA
NCT04365101	Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNKCOVID)	Randomized-controlled	Allogeneic off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.	86	Phase I/II	USA
NCT04280224	NK Cells Treatment for COVID-19	Randomized	NK-cells	30	Phase I - Recruiting	China
NCT04324996	A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19	Randomized	CAR-NK cells are universal off-the-shelf NK cells enriched from umbilical cord blood and engineered genetically.	90	Phase I/II - Unknown	China
NCT04578210	Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia (RELEASE)	Randomized	Single infusion of NK from a healthy donor recovered from COVID-19	84	Completed	Spain
NCT04363346	Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia	Non-randomized	FT516: off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.	5	Completed	USA

NCT number: National Clinical Trial Number. Data retrieved from https://clinicaltrials.gov/.